Iovance Biotherapeutics (IOVA) Q1 2026 earnings summary

Executive summary

• Achieved 45% year-over-year revenue growth to $71.4M in Q1 2026, driven by strong Amtagvi and Proleukin sales, operational efficiencies, and AMTAGVI adoption reaching all-time highs.

• Net loss narrowed by 32% to $79.0M, reflecting higher sales and reduced operating expenses.

• Commercial launch of Amtagvi in the U.S. progressing, with expansion plans for global markets and first ex-U.S. treatment center authorized in Canada.

• Manufacturing centralized at iCTC, with completed facility upgrades and transition to internal manufacturing improving cost efficiency and scalability.

• Strategic restructuring in August 2025 reduced workforce by 19% to optimize costs.

Financial highlights

• Q1 2026 revenue was $71.4M, up from $49.3M in Q1 2025; Amtagvi revenue reached $60.2M, Proleukin revenue $11.2M.

• Gross margin for Q1 was 41%, impacted by one-time facility upgrade costs but improved due to operational efficiencies.

• R&D expenses declined for the third consecutive quarter, down 18% year-over-year and 12% sequentially; SG&A expense down 11% year-over-year.

• Net loss for Q1 2026 was $79M, improved from $116M in Q1 2025; EPS $(0.19) vs. $(0.36) prior year.

• Cash and equivalents totaled $319M as of March 31, 2026, with operations funded into 2028.

Outlook and guidance

• Q2 2026 total revenue guidance: $86–$88M; Amtagvi revenue expected at $79–$81M, a 23% increase over Q4 2025.

• Full-year 2026 revenue guidance: $350–$370M, predominantly from Amtagvi.

• Projected $1B peak sales trajectory for Amtagvi and Proleukin in the U.S.

• Expansion to at least 110 authorized treatment centers by year-end 2026.

• Sufficient capital to fund operations for at least 12 months from reporting date; cash reserves and expense reductions expected to support operations into 2028.